---
schema_version: "secwatch.filing_event.v1"
accession: "0001396814-23-000008"
form_type: "8-K"
ticker: "PCRX"
cik: "0001396814"
company_name: "Pacira BioSciences, Inc."
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T21:39:07.897710+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Pacira BioSciences reports record 2022 revenue of $667M; Q4 GAAP net loss widens to $10.1M

## Summary
- Full-year 2022 revenue $666.8M (+23% YoY); GAAP net income $15.9M ($0.34 diluted EPS) vs $42.0M ($0.92) in 2021.
- Q4 2022 revenue $172.0M (+8% YoY); GAAP net loss $10.1M ($0.22 loss per share) vs loss $5.1M in Q4 2021.
- ZILRETTA net sales $105.5M full year; Q4 $28.0M (+121% YoY) driving growth. EXPAREL $536.9M (+6%) full year; Q4 $138.0M (-1%).
- 2023 guidance: EXPAREL net sales $570-580M, ZILRETTA $115-125M, non-GAAP gross margin 76-78%.
- Submitted sNDA for EXPAREL sciatic/femoral nerve blocks; opened Houston Innovation & Training Center in Jan 2023.

## SEC filing metadata
- accession: 0001396814-23-000008
- form_type: 8-K
- ticker: PCRX
- cik: 0001396814
- company_name: Pacira BioSciences, Inc.
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1396814/000139681423000008/0001396814-23-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1396814/000139681423000008/pcrx-20230228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001396814-23-000008
- JSON: https://secwatch.observer/filing/0001396814-23-000008.json
- Plain text: https://secwatch.observer/filing/0001396814-23-000008.txt

## Key facts
- Earnings Releases
  Pacira BioSciences, Inc. reported the fourth quarter ended December 31, 2022 results: revenue $172.0 million, net income $10.1 million, EPS $0.22 per basic and diluted share.
  - Period: the fourth quarter ended December 31, 2022
  - Revenue: $172.0 million
  - Net income: $10.1 million
  - EPS: $0.22 per basic and diluted share
  - Result: reported results
  source text: Full-year revenues of $666.8 million and fourth quarter revenues of $172.0 million. • Full-year GAAP net income of $15.9 million or $0.35 per basic share and $0.34 per diluted share. • Fourth quarter GAAP net loss of $10.1 million or $0.22 per basic and diluted share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1396814/000139681423000008/0001396814-23-000008-index.htm
- Earnings Releases
  Pacira BioSciences, Inc. reported the full-year ended December 31, 2022 results: revenue $666.8 million, net income $15.9 million, EPS $0.35 per basic share and $0.34 per diluted share.
  - Period: the full-year ended December 31, 2022
  - Revenue: $666.8 million
  - Net income: $15.9 million
  - EPS: $0.35 per basic share and $0.34 per diluted share
  - Result: reported results
  source text: Full-year revenues of $666.8 million and fourth quarter revenues of $172.0 million. • Full-year GAAP net income of $15.9 million or $0.35 per basic share and $0.34 per diluted share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1396814/000139681423000008/0001396814-23-000008-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.